Evidence map›Paper›PMID 37164153›Full record

ArticleJournal of substance use and addiction treatment2023

Impact of VA's video telehealth tablets on substance use disorder care during the COVID-19 pandemic.

Kritee Gujral, James Van Campen, Josephine Jacobs, Rachel Kimerling, Donna M Zulman, Daniel Blonigen

Open access · bronzeAbstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Kritee GujralHealth Economics Resource Center, VA Palo Alto Health Care System, Menlo Park, CA, United States of America; Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Menlo Park, United States of America. Electronic address: kritee.gujral@va.gov.
James Van CampenCenter for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Menlo Park, United States of America.
Josephine JacobsHealth Economics Resource Center, VA Palo Alto Health Care System, Menlo Park, CA, United States of America; Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Menlo Park, United States of America.
Rachel KimerlingCenter for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Menlo Park, United States of America; National Center for Post-Traumatic Stress Disorder, VA Palo Alto Health Care System, Menlo Park, United States of America.
Donna M ZulmanCenter for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Menlo Park, United States of America; Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Daniel BlonigenCenter for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Menlo Park, United States of America; Department of Psychiatry and Behavioral Sciences, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
VA Palo Alto Health Care System · US

Funding

HSRD VA IK6 HX003763
6 · The paper itself

Abstract

backgroundTelehealth has the potential to improve health care access for patients but it has been underused and understudied for examining patients with substance use disorders (SUD). VA began distributing video-enabled tablets to veterans with access barriers in 2016 to facilitate participation in home-based telehealth and expanded this program in 2020 due to the coronavirus COVID-19 pandemic.

objectiveExamine the impact of VA's video-enabled telehealth tablets on mental health services for patients diagnosed with SUD.

methodsThis study included VA patients who had ≥1 mental health visit in the calendar year 2019 and a documented diagnosis of SUD. Using difference-in-differences and event study designs, we compared outcomes for SUD-diagnosed patients who received a video-enabled tablet from VA between March 15th, 2020 and December 31st, 2021 and SUD-diagnosed patients who never received VA tablets, 10 months before and after tablet-issuance. Outcomes included monthly frequency of SUD psychotherapy visits, SUD specialty group therapy visits and SUD specialty individual outpatient visits. We examined changes in video visits and changes in visits across all modalities of care (video, phone, and in-person). Regression models adjusted for several covariates such as age, sex, rurality, race, ethnicity, physical and mental health chronic conditions, and broadband coverage in patients' residential zip-code.

resultsThe cohort included 21,684 SUD-diagnosed tablet-recipients and 267,873 SUD-diagnosed non-recipients. VA's video-enabled tablets were associated with increases in video visits for SUD psychotherapy (+3.5 visits/year), SUD group therapy (+2.1 visits/year) and SUD individual outpatient visits (+1 visit/year), translating to increases in visits across all modalities (in-person, phone and video): increase of 18 % for SUD psychotherapy (+1.9 visits/year), 10 % for SUD specialty group therapy (+0.5 visit/year), and 4 % for SUD specialty individual outpatient treatment (+0.5 visit/year).

conclusionsVA's distribution of video-enabled tablets during the COVID-19 pandemic were associated with higher engagement with video-based services for SUD care among patients diagnosed with SUD, translating to modest increases in total visits across in-person, phone and video modalities. Distribution of video-enabled devices can offer patients critical continuity of SUD therapy, particularly in scenarios where they have heightened barriers to in-person care.

Indexed as

COVID-19Substance-Related DisordersTelemedicineHumansPandemicsTabletsTabletsAlcohol use disorderOpioid use disorderSmart devicesSubstance abuseSubstance use disorderSUD care during COVID-19SUD group therapySUD psychotherapySUD treatment visitsSUD videoTelehealthTelemedicineVA iPadVA tabletVA telehealth

Identifiers

PMID37164153
PMCPMC10164656
OpenAlexW4375844647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.